Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517515 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL2292403 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL26077407 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL517516 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL2273817 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL5768083 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL20766014 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL29673228 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL20778648 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL20794795 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347349-B1 | FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2019-09-18 | — | — | EP | disclosed |
| US-10294217-B2 | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators | SUVEN LIFE SCIENCES LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-9629836-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-9629836-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| WO-2017042643-A1 | FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
| US-20150051209-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS AG (CH) | 2015-02-19 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| US-5837715-A | 3-fluoro-4-aminopiperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051209-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NRAS, BRAF, KRAS | USP30 3806/4885GPR119 2532/4885STS 4078/4885 |
| US-10294217-B2 | Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM3 | USP30 3202/4885GPR119 83/4885STS 4601/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | USP30 3078/4885GPR119 1947/4885STS 830/4885 |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NRAS, BRAF, KRAS | USP30 3806/4885GPR119 2532/4885STS 4078/4885 |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NRAS, BRAF, KRAS | USP30 3806/4885GPR119 2532/4885STS 4078/4885 |
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | USP30 3209/4885GPR119 2446/4885STS 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.